



Media Contact:

Michael Ventriello / Lanmark Group
732-389-4500 Ext. 181
mventriello@lanmarkgroup.com

For Immediate Release:

**ORALDNA LABS INTRODUCES TWO SALIVARY DNA TESTS
TO SUPPORT DENTISTS' FIGHT AGAINST PERIODONTAL DISEASE**

***Molecular DNA Tests Positioning Dental Professionals at the Forefront of Oral
Medicine - Company Planning the Launch of HPV/Oral Cancer DNA Test in 2010***

Nashville, TN – November 16, 2009 – OralDNA Labs™ Inc. (www.OralDNA.com), a specialty diagnostics subsidiary of Quest Diagnostics® Incorporated (NYSE: DGX) focused on bringing advanced laboratory testing to the dental community, today announced the availability of two revolutionary molecular tests to help periodontists and general dentists identify patients with and at risk for periodontal disease. MyPerioPathsm detects the presence and quantity of specific bacteria associated with periodontal disease, while MyPerioIDsm PST[®], which the company licenses from Interleukin Genetics, provides a means of quickly and accurately¹ assessing an individual's genetic risk for periodontal disease.

Used together, the new salivary DNA diagnostic tests can help dental professionals reduce patient incidence of periodontal disease. MyPerioPathsm provides early and accurate¹ diagnosis of existing periodontal disease by identifying and measuring specific types of bacteria, while MyPerioIDsm PST[®] assesses a patient's genetic predisposition to developing periodontal disease well before physical symptoms occur. The company has launched a national dental industry awareness and training program to support the profession's understanding and effective use of the new tools.

According to OralDNA Inc. senior vice president and general manager Robert Walker, the company has been introducing the tests to leading dental industry practitioners during the past year. "Leading periodontists and general dentists are already relying

on the MyPerioPathsm and MyPerioIDsm PST[®] salivary diagnostic tests to provide valuable insights for enhanced patient care, and as important tools in the fight against periodontal disease. We believe these tests will not only help put dental professionals at the forefront of oral medicine, but also enable them to provide more comprehensive and accurate treatment plans for their patients.”

According to the American Dental Association, an estimated 75% of all Americans over the age of 35 have some form of periodontal disease² and research conducted during the past 10 years has provided insight into the Perio / Systemic Connection and the link between chronic periodontal infections and heart disease, diabetes, stroke, and some forms of cancer.^{3,4}

Within the next year, OralDNA expects to add the clinician-administered oral DNA HPV test, OraRisksm HPV, for use in assessing the risks associated with certain types of oral cancer, and intends to continue to broaden its menu of salivary diagnostic tests for use in oral medicine.

For more information, education, and training related to OralDNA's salivary DNA diagnostic tests, dental professionals, including periodontists, general dentists, and dental hygienists, should visit www.OralDNAtraining.com or call (877) 577-9055.

About OralDNA Labs™ Inc. (www.OralDNA.com)

OralDNA Labs Inc., a subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), is a specialty diagnostics company created to advance clinical testing in the dental community. The company's goal is to help the dental profession achieve better clinical outcomes by providing reliable, definitive, and cost-effective clinical tests that drive the detection and prognosis of disease at an earlier, more treatable stage, with an initial focus on periodontal disease. OralDNA offers two DNA-Polymerase Chain Reaction (PCR) tests for periodontal disease diagnosis and genetic susceptibility: MyPerioPathsm detects the presence and quantity of specific bacteria associated with periodontal disease, while MyPerioIDsm PST[®], which is licensed through a marketing, sales, and distribution agreement with Interleukin Genetics, provides a means of assessing an individual's genetic risk for periodontal disease. The company has also developed an oral HPV test named OraRisksm HPV for use in assessing the risks associated with certain types of oral cancer.

About Quest Diagnostics®

Quest Diagnostics is the world's leading provider of diagnostic testing, information, and services that patients and clinicians need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com.

REFERENCES:

1. Data on file, OralDNA Labs Inc.
2. Genco R, Offenbacher S, Beck J. Periodontal disease and cardiovascular disease: epidemiology and possible mechanisms. *JADA* 2002;133(Suppl.):14S-22S.
3. Friedewald VE, Kornman KS, Beck JD, et al. *The American Journal of Cardiology* and *Journal of Periodontology* editors' consensus: periodontitis and atherosclerotic cardiovascular disease. *J Periodontol* 2009;80:1021-1032.
4. Van Dyke TE. The management of inflammation in periodontal disease. *J Periodontol* 2008;79:1601-1608.

###